Iñigo Rua-Figueroa, Natalia Pérez-Veiga, Esther Rodríguez-Almaraz, María Galindo-Izquierdo, Celia Erausquin, Antonio Fernandez-Nebro, Esther Uriarte Itzazelaia, Belén Serrano-Benavente, Jaime Calvo ...

Objective Both belimumab and telitacicept are recognised blockers for B lymphocyte activation, both of which have been approved as add-on therapies for SLE in China. The aim of this study is to ...

Objective This study examined the prevalence of major adverse cardiovascular events (MACE) among Saudi patients with SLE and the general population and considered factors associated with such outcomes ...

Objective Changes in the care of patients with SLE dictate a re-evaluation of its natural history and risk factors for disease deterioration and damage accrual. We sought to decipher factors ...

Objective Combination therapy with rituximab and belimumab is a novel treatment strategy for severe SLE and lupus nephritis. Phase II studies have shown promising results, although long-term data are ...

Lupus Science & Medicine® is a global, peer reviewed, open access online journal that provides a central point for publication of basic, clinical, translational, and epidemiological studies of all ...

Objective CC-97540 (BMS-986353) is an investigational CD19 CAR T-cell therapy utilizing the lisocabtagene maraleucel CD19-directed CAR T construct with a 41BB co-stimulatory domain and an epidermal ...

Background B cells are a common therapeutic target in SLE but responses are mixed suggesting that some aspects of disease are less B cell-dependent. Transcriptomic analyses have revealed ...

Objective BAFF and APRIL signal through TACI, BCMA, and/or BAFF-R, and play important roles in the activation, differentiation, and/or survival of B cells, particularly antibody-secreting cells, as ...

Background Diets deficient in fibers are prevalent in modern societies and implicated in gut microbial dysbiosis contributing to the pathogenesis of chronic inflammatory disorders. 1 A particular type ...

Objective To develop an improved score for prediction of severe infection in patients with systemic lupus erythematosus (SLE), namely, the SLE Severe Infection Score-Revised (SLESIS-R) and to validate ...

Aims To characterise patients with refractory SLE receiving rituximab biosimilar (CT-P10) and to explore short-term efficacy and safety associated with rituximab biosimilar use.Methods We ...